Isis Pharmaceuticals SVP C Frank Bennett Unloads 10,000 Shares (ISIS)
Isis Pharmaceuticals (NASDAQ:ISIS) SVP C Frank Bennett sold 10,000 shares of Isis Pharmaceuticals stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $30.23, for a total value of $302,300.00. Following the completion of the transaction, the senior vice president now directly owns 2,866 shares in the company. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
ISIS has been the subject of a number of recent research reports. Analysts at Canaccord Genuity raised their price target on shares of Isis Pharmaceuticals (NASDAQ:ISIS) from $23.00 to $27.00 in a research note to investors on Tuesday. They now have a “hold” rating on the stock. Separately, analysts at Goldman Sachs Group Inc. initiated coverage on shares of Isis Pharmaceuticals (NASDAQ:ISIS) in a research note to investors on Wednesday, September 4th. They set a “neutral” rating and a $26.00 price target on the stock. Finally, analysts at Zacks downgraded shares of Isis Pharmaceuticals (NASDAQ:ISIS) from an “outperform” rating to a “neutral” rating in a research note to investors on Tuesday, August 20th. They now have a $27.00 price target on the stock.
Two research analysts have rated the stock with a sell rating, five have issued a hold rating and five have issued a buy rating to the stock. Isis Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $29.20.
Shares of Isis Pharmaceuticals (NASDAQ:ISIS) traded down 0.92% during mid-day trading on Wednesday, hitting $31.33. 911,574 shares of the company’s stock traded hands. Isis Pharmaceuticals has a 1-year low of $7.56 and a 1-year high of $34.31. The stock’s 50-day moving average is $27.52 and its 200-day moving average is $23.15. The company’s market cap is $3.613 billion.
Isis Pharmaceuticals (NASDAQ:ISIS) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.09) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.21) by $0.12. The company had revenue of $38.10 million for the quarter, compared to the consensus estimate of $26.76 million. During the same quarter in the previous year, the company posted ($0.01) earnings per share. The company’s revenue for the quarter was down 19.5% on a year-over-year basis. On average, analysts predict that Isis Pharmaceuticals will post $-0.56 earnings per share for the current fiscal year.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.